CD19 and systemic lupus erythematosus: Based on this rationale, Obexelimab, a monoclonal antibody targeting CD19 and leading to the inhibition of B cell activation, was assessed in a phase 2 randomized, placebo-controlled trial in patients with moderate-to-severe SLE [59,60].